XM không cung cấp dịch vụ cho cư dân của Mỹ.
G
G

GSK


Tin tức

Boehringer Ingelheim faces second hung jury in Chicago Zantac trial

UPDATE 1-Boehringer Ingelheim faces second hung jury in Chicago Zantac trial Hung jury in latest Zantac cancer trial in Chicago Boehringer Ingelheim only defendant after settlements with GSK, Pfizer FDA pulled Zantac in 2020 over NDMA carcinogen concerns Updates Sept 18 story with statement from Boehringer Ingelheim in paragraph 5 By Brendan Pierson Sept 18 (Reuters) - The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, as j
G
P
S

Boehringer Ingelheim faces second hung jury in Chicago Zantac trial

UPDATE 1-Boehringer Ingelheim faces second hung jury in Chicago Zantac trial Hung jury in latest Zantac cancer trial in Chicago Boehringer Ingelheim only defendant after settlements with GSK, Pfizer FDA pulled Zantac in 2020 over NDMA carcinogen concerns Updates Sept 18 story with statement from Boehringer Ingelheim in paragraph 5 By Brendan Pierson Sept 18 (Reuters) - The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, as j
G
P
S

A second Zantac cancer trial ends with hung jury

A second Zantac cancer trial ends with hung jury Hung jury in latest Zantac cancer trial in Chicago Boehringer Ingelheim only defendant after settlements with GSK, Pfizer FDA pulled Zantac in 2020 over NDMA carcinogen concerns By Brendan Pierson Sept 18 (Reuters) - The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, as jurors in Chicago were unable to agree on whether Boehringer Ingelheim must pay damages to an Illinois man
G
P
S

GSK settles two California lawsuits related to heartburn drug Zantac

UPDATE 1-GSK settles two California lawsuits related to heartburn drug Zantac Adds background and context Sept 18 (Reuters) - British drugmaker GSK GSK.L said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued heartburn drug Zantac caused cancer. GSK does not admit to any liability in either settlement, it said in a statement.
G
P
S

GSK's RSV, Shingles vaccines show on-par immune response in joint trial

UPDATE 1-GSK's RSV, Shingles vaccines show on-par immune response in joint trial Adds details on study in paragraph 2, company's statement in paragraph 4 Sept 18 (Reuters) - British drugmaker GSK GSK.L said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
G

GSK's RSV vaccine meets main goal when co-administered with shingles shot

GSK's RSV vaccine meets main goal when co-administered with shingles shot Sept 18 (Reuters) - British drugmaker GSK GSK.L said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults over 50 years of age. The company said co-administration of the vaccines generated an immune response that was at least on-par with separate administration.
G

Gsk Says Japan Accepts NDA For Blenrep In Multiple Myeloma

BRIEF-Gsk Says Japan Accepts NDA For Blenrep In Multiple Myeloma Sept 17 (Reuters) - GSK plc GSK.L : GSK PLC - JAPAN FILING ACCEPTANCE: BLENREP MULTIPLE MYELOMA Source text for Eikon: ID:nRSQ4071Ea Further company coverage: GSK.L
G

Iteos falls after mid-stage study results for lung cancer drug

BUZZ-Iteos falls after mid-stage study results for lung cancer drug Updates ** Shares of cancer drug developer Iteos Therapeutics ITOS.O slide 23.6% to $12.76 ** Stock had risen 27 .3% t o $21.26 in premarket trade ** Co says its lung cancer drug belrestotug, in combination with GSK's GSK.L drug dostarlimab, showed higher percentage of reduction or
G

Iteos rises on superior efficacy of lung cancer drug combo vs GSK’s Jemperli alone

BUZZ-Iteos rises on superior efficacy of lung cancer drug combo vs GSK’s Jemperli alone ** Shares of cancer drug developer Iteos Therapeutics ITOS.O rise 14.7% at $19.16 premarket ** Co says its lung cancer drug, belrestotug, in combination with GSK's GSK.L drug, dostarlimab, showed reduction or disappearance of tumor in 63.3%-76.7% patients, vs
G

Zenas BioPharma shares rise nearly 8% in market debut

UPDATE 2-Zenas BioPharma shares rise nearly 8% in market debut Adds details on U.S. IPO market in paragraph 4-5, details on the company from paragraph 6 onwards Sept 13 (Reuters) - Shares of Bristol-Myers Squibb-backed Zenas BioPharma ZBIO.O rose nearly 8% in their Nasdaq debut on Friday, a sign of recovery for the U.S. initial public offering market in 2024 after two subpar years.
C
G

GSK's Blenrep Receives Breakthrough Therapy Designation In China

BRIEF-GSK's Blenrep Receives Breakthrough Therapy Designation In China Sept 13 (Reuters) - GSK plc GSK.L : GSK PLC - CHINA BREAKTHROUGH THERAPY DESIGNATION FOR BLENREP GSK PLC - BLENREP RECEIVES BREAKTHROUGH THERAPY DESIGNATION IN CHINA Source text for Eikon: ID:nRSM0429Ea Further company coverage: GSK.L
G

Antifungal drug developer F2G raises $100 mln to fight 'superbugs', fund late-stage trial

Antifungal drug developer F2G raises $100 mln to fight 'superbugs', fund late-stage trial By Kashish Tandon Sept 12 (Reuters) - F2G said on Thursday it has raised $100 million from investors including AMR Action Fund, backed by large drugmakers such as Johnson & Johnson and Pfizer, to help it develop treatments for infections caused by drug resistant "superbugs" or microbes.
G
P

UK Stocks-Factors to watch on Sept 12

UPDATE 1-UK Stocks-Factors to watch on Sept 12 Adds news items, updates futures Sept 12 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher on Thursday, with futures FFIc1 up 1.2%. * GSK: British drugmaker GSK GSK.L announced positive results from its mid-stage trial of its seasonal influenza vaccine programme using the messenger RNA (mRNA) technology, saying it would now progress to late-stage clinical development.
G
S
D
R

British drugmaker GSK moves mRNA flu vaccine to late-stage trials

UPDATE 1-British drugmaker GSK moves mRNA flu vaccine to late-stage trials Adds details and background throughout Sept 12 (Reuters) - British drugmaker GSK GSK.L announced on Thursday positive results from a mid-stage trial of its seasonal influenza vaccine programme using the messenger RNA (mRNA) technology, and said it would now progress to late-stage clinical development.
G

GSK's mRNA flu vaccine programme to proceed to late-stage trials

GSK's mRNA flu vaccine programme to proceed to late-stage trials Sept 12 (Reuters) - British drugmaker GSK GSK.L on Thursday announced positive results from its mid-stage trial of its seasonal influenza vaccine programme using the messenger RNA (mRNA) technology, saying it would now progress to late-stage clinical development. Data showed a vaccine candidate formulation demonstrated positive A and B strain immune responses relative to standard of care in both younger and older adults, GSK said.
G

GSK Announces Positive MRNA Flu Vaccine Phase II Headline Data

BRIEF-GSK Announces Positive MRNA Flu Vaccine Phase II Headline Data Sept 12 (Reuters) - GSK plc GSK.L : POSITIVE MRNA FLU VACCINE PHASE II HEADLINE DATA VACCINE CANDIDATE SHOWS POSITIVE IMMUNE RESPONSES IN YOUNGER AND OLDER ADULTS DATA SUPPORT PROGRESSION TO PHASE III CLINICAL TRIALS MRNA INFLUENZA VACCINE PROGRAMME TO PROGRESS TO LATE-STAGE DEVEL
G

UK Stocks-Factors to watch on Sept 11

UPDATE 1-UK Stocks-Factors to watch on Sept 11 Adds news items, updates futures Sept 11 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher on Wednesday, with futures up 0.15%. * RIGHTMOVE: Britain's largest real estate portal Rightmove RMV.L rejected the 5.6 billion pound ($7.32 billion) cash-and-stock takeover proposal from Australia's REA Group REA.AX , it said, citing that the bid undervalued its prospects.
B
G
N
R
R
A

GSK's experimental herpes vaccine fails to meet main goal in trial

UPDATE 1-GSK's experimental herpes vaccine fails to meet main goal in trial Adds details on the virus and GSK's next moves from paragraph 2 Sept 11 (Reuters) - British drugmaker GSK GSK.L said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main goal of a mid-stage trial and would not be taken forward to a late-stage trial.
G

GSK Says GSK3943104 HSV Vaccine Candidate Fails To Meet Primary Efficacy Objective

BRIEF-GSK Says GSK3943104 HSV Vaccine Candidate Fails To Meet Primary Efficacy Objective Sept 11 (Reuters) - GSK plc GSK.L : GSK PLC - UPDATE ON PHASE I/II THERAPEUTIC HSV VACCINE TRIAL GSK PLC - COMPLETES PRIMARY DATA ANALYSIS OF PHASE II HSV VACCINE TRIAL GSK PLC - GSK3943104 HSV VACCINE CANDIDATE FAILS TO MEET PRIMARY EFFICACY OBJECTIVE GSK PLC
G

GSK's experimental HSV vaccine fails to meet main goal in trial

GSK's experimental HSV vaccine fails to meet main goal in trial Sept 11 (Reuters) - British drugmaker GSK GSK.L said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main goal of a mid-stage trial and would not be taken forward to a late-stage trial. Reporting by Yadarisa Shabong in Bengaluru; Editing by
G



Các điều kiện

Các tài sản phổ thông

Khước từ trách nhiệm: các tổ chức thuộc XM Group chỉ cung cấp dịch vụ khớp lệnh và truy cập Trang Giao dịch trực tuyến của chúng tôi, cho phép xem và/hoặc sử dụng nội dung có trên trang này hoặc thông qua trang này, mà hoàn toàn không có mục đích thay đổi hoặc mở rộng. Việc truy cập và sử dụng như trên luôn phụ thuộc vào: (i) Các Điều kiện và Điều khoản; (ii) Các Thông báo Rủi ro; và (iii) Khước từ trách nhiệm toàn bộ. Các nội dung như vậy sẽ chỉ được cung cấp dưới dạng thông tin chung. Đặc biệt, xin lưu ý rằng các thông tin trên Trang Giao dịch trực tuyến của chúng tôi không phải là sự xúi giục, mời chào để tham gia bất cứ giao dịch nào trên các thị trường tài chính. Giao dịch các thị trường tài chính có rủi ro cao đối với vốn đầu tư của bạn.

Tất cả các tài liệu trên Trang Giao dịch trực tuyến của chúng tôi chỉ nhằm các mục đích đào tạo/cung cấp thông tin và không bao gồm - và không được coi là bao gồm - các tư vấn tài chính, đầu tư, thuế, hoặc giao dịch, hoặc là một dữ liệu về giá giao dịch của chúng tôi, hoặc là một lời chào mời, hoặc là một sự xúi giục giao dịch các sản phẩm tài chính hoặc các chương trình khuyến mãi tài chính không tự nguyện.

Tất cả nội dung của bên thứ ba, cũng như nội dung của XM như các ý kiến, tin tức, nghiên cứu, phân tích, giá cả, các thông tin khác hoặc các đường dẫn đến trang web của các bên thứ ba có trên trang web này được cung cấp với dạng "nguyên trạng", là các bình luận chung về thị trường và không phải là các tư vấn đầu tư. Với việc các nội dung đều được xây dựng với mục đích nghiên cứu đầu tư, bạn cần lưu ý và hiểu rằng các nội dung này không nhằm mục đích và không được biên soạn để tuân thủ các yêu cầu pháp lý đối với việc quảng bá nghiên cứu đầu tư này và vì vậy, được coi như là một tài liệu tiếp thị. Hãy chắc chắn rằng bạn đã đọc và hiểu Thông báo về Nghiên cứu Đầu tư không độc lập và Cảnh báo Rủi ro tại đây liên quan đến các thông tin ở trên.

Cảnh báo rủi ro: Vốn của bạn bị rủi ro. Các sản phẩm có đòn bẩy có thể không phù hợp với tất cả mọi người. Hãy xem kỹ Thông báo rủi ro của chúng tôi.